

## WEST Search History

DATE: Thursday, May 27, 2004

### Hide? Set Name Query

### Hit Count

*DB=USPT; PLUR=YES; OP=AND*

	<u>Query</u>	<u>Hit Count</u>
<input type="checkbox"/>	L1 suppository.ti,clm.	1388
<input type="checkbox"/>	L2 suppository.ab.	253
<input type="checkbox"/>	L3 (L2 or l1) and (peg or polyethylene or poly-ethylene or peg\$4)	687
<input type="checkbox"/>	L4 L3 and (poly-sorbate or polysorbate)	80
<input type="checkbox"/>	L5 (L2 or l1) and (peg or polyethylene or poly-ethylene or peg\$4).ti,ab,clm.	113
<input type="checkbox"/>	L6 L3 and (poly-sorbate or polysorbate).ti,ab,clm.	8
<input type="checkbox"/>	L7 L6 and l5	7
<input type="checkbox"/>	L8 hertelendy.in.	16
<input type="checkbox"/>	L9 L8 and supposito\$	1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 7 of 7 returned.**

---

1. [6451339](#). 02 Jul 01; 17 Sep 02. Compositions and methods for improved delivery of hydrophobic agents. Patel; Mahesh V., et al. 424/451; 424/435 424/450 424/455 424/456 424/463 424/464 424/489 424/499 424/502 514/937 514/938 514/939 514/940 514/941 514/942 514/943 514/975. A61K009/127.

---

2. [6383471](#). 06 Apr 99; 07 May 02. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents. Chen; Feng-Jing, et al. 424/45; 424/401 424/436 424/451 424/46 514/944. A61K009/12.

---

3. [6340479](#). 28 Nov 00; 22 Jan 02. Stable, homogeneous, extract free or nearly free form secondary reaction products. Kreuter; Matthias H., et al. 424/725; 424/400 424/730 424/754 424/756. A61K035/78.

---

4. [6309663](#). 17 Aug 99; 30 Oct 01. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents. Patel; Mahesh V., et al. 424/450; 424/435 424/451 424/455 424/456 424/463 424/464 424/489 424/499 424/502 514/937 514/938 514/939 514/940 514/941 514/942 514/943 514/975. A61K009/127.

---

5. [6267985](#). 30 Jun 99; 31 Jul 01. Clear oil-containing pharmaceutical compositions. Chen; Feng-Jing, et al. 424/451; 424/43 424/433 424/436 424/441 424/443 424/455 424/456 424/458 424/463 424/464 424/465 424/489 424/490 424/731 424/735 424/750 424/757 424/764 514/44 514/772.2 514/772.3 514/777 514/778 514/779 514/781 514/783 514/784 514/785 514/786 514/937 514/944. A61K009/08 A61K009/10 A61K009/14 A61K009/20 A61K009/48.

---

6. [6099853](#). 04 Sep 97; 08 Aug 00. Vaginal suppository vaccine for urogenital infections. Hertelendy; Zsolt Istvan, et al. 424/433; 424/203.1 424/436. A61K009/02 A61K039/116.

---

7. [5853767](#). 02 Jan 97; 29 Dec 98. Compositions for treating fungal, parasitic and/or bacterial infections, especially infections of organs such as the skin and vagina. Melman; Steven A.. 424/659; 514/557. A61K033/22 A61K031/19.

---

[Generate Collection](#)[Print](#)

Terms	Documents
L6 and L5	7

[Prev Page](#)   [Next Page](#)   [Go to Doc#](#)

First Hit    Fwd Refs

L7: Entry 1 of 7

File: USPT

Sep 17, 2002

US-PAT-NO: 6451339

DOCUMENT-IDENTIFIER: US 6451339 B2

**\*\* See image for Certificate of Correction \*\***

TITLE: Compositions and methods for improved delivery of hydrophobic agents

DATE-ISSUED: September 17, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Patel; Mahesh V.	Salt Lake City	UT		
Chen; Feng-Jing	Salt Lake City	UT		

US-CL-CURRENT: 424/451; 424/435, 424/450, 424/455, 424/456, 424/463, 424/464,  
424/489, 424/499, 424/502, 514/937, 514/938, 514/939, 514/940, 514/941, 514/942,  
514/943, 514/975

## CLAIMS:

What is claimed and desired to be secured by United States Letters Patent is:

1. A pharmaceutical formulation for administration of a hydrophobic lipid-regulating agent, comprising a therapeutically effective amount of the lipid-regulating agent and a carrier comprised of (a) at least one hydrophilic surfactant selected from the group consisting of hydrophilic non-ionic surfactants, hydrophilic ionic surfactants, and combinations thereof, and (b) at least one hydrophobic surfactant having an HLB value less than about 10 and selected from the group consisting of alcohols; polyoxyethylene alkylethers; fatty acids; glycerol fatty acid monoesters; glycerol fatty acid diesters; acetylated glycerol fatty acid monoesters; acetylated glycerol fatty acid diesters, lower alcohol fatty acid esters; polyethylene glycol fatty acid esters; polyethylene glycol glycerol fatty acid esters; polypropylene glycol fatty acid esters; polyoxyethylene glycerides; lactic acid derivatives of monoglycerides; lactic acid derivatives of diglycerides; propylene glycol diglycerides; sorbitan fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; transesterified vegetable oils; sterols; sterol derivatives; sugar esters; sugar ethers; sucroglycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils, reaction products of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; and mixtures thereof, said hydrophilic and hydrophobic surfactants being present in amounts such that upon dilution with an aqueous solution at an aqueous solution to carrier ratio of 100:1 by weight, the carrier forms a clear aqueous dispersion having an absorbance of less than about 0.1 at a wavelength of about 400 nm, and wherein the composition is substantially free of glycerol triesters of C.<sub>sub.6</sub> to about C.<sub>sub.25</sub> fatty acids.

2. The formulation of claim 1, wherein the lipid regulating agent is selected from the group consisting of atorvastatin, bezafibrate, cerivastatin, ciprofibrate, clofibrate, fenofibrate, fluvastatin, gemfibrozil, pravastatin, probucol, simvastatin, and combinations thereof.